Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: GlaxoSmithKline
Woman Max 99 years
GlaxoSmithKline Research & Development
Update Il y a 4 ans
An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women with Overactive Bladder
The primary objective of this study is to compare the efficacy of solabegron 125mg and 50mg administered twice daily, to that of placebo in female subjects with OAB including symptoms of urgency with ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and Seretide 50/500mcg alone) in the treatment of subjects with COPD
The primary objective of the study is to compare the effects of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily with the individual treatments (tiotropium bromide 18mcg once da...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline, S.A
Update Il y a 4 ans
Estudio fase III, no aleatorizado, abierto para evaluar la seguridad e inmunogenicidad de la vacuna H1N1 adyuvada con AS03A administrada como primovacunación y booster en sujetos entre 3 y 17 años de edad
Evaluar la respuesta inmune humoral después la administración de dos dosis primarias de la vacuna pandémica experimental H1N1 que alcance o exceda los objetivos normativos (CPMH) de la AEM para la ta...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase III, double-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological non-inferiority of two manufacturing processes of the A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A
•To evaluate the immunological non-inferiority (in terms of HI antibody GMTs) of the two H1N1 vaccines, 21d after 1st vaccination
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development
Update Il y a 4 ans
Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via nasal Biopsy in Subjects ≥18 Years of Age with Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to determine effects to the nasal mucosa of PAR subjects after one year of continuous treatment with GW685698X aqueous nasal spray 100mcg QD compared to a mometa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
The vaccine response and long-term antibody persistence of GSK Biologicals’ MenACWY-TT vaccine (GSK134612) administered as one dose at 6 years post-MenC primary vaccination in healthy subjects aged 12-18 months at primary vaccination
•To evaluate the immunogenicity of MenACWY-TT conjugate vaccine in terms of the percentage of subjects with an rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY vaccine response*. *Vaccine response to m...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 4 ans
A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered either once daily or twice daily, compared with placebo, as effective monotherapy in the treatment of uncomplicated acute rhinosinusitis (ARS) in adult and adolescent subjects 12 years of age and older
The objective of this study is to evaluate the safety and efficacy of two doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as monotherapy in the treatment of adult and ad...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Study to evaluate the safety of Rotarix™ in Chinese children
To assess the reactogenicity of a single oral dose of GSK Biologicals’ liquid HRV vaccine when compared to placebo group, in terms of solicited AEs in healthy children aged 2 to 6 years
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), through evaluation of early antibody responses after an additional dose of 10Pn-PD-DiT at 40-48 months of age, to evaluate in the fourth year of life, the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine and the impact of pneumococcal vaccination on nasopharyngeal carriage
•To demonstrate the immunological memory induced following primary vaccination in study 10PN-PD-DIT-010 (107017) and booster vaccination in study 10PN-PD-DIT-014 (107137) with the 10Pn-PD-DiT vaccine,...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research & Development Ltd
Update Il y a 4 ans
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD
The primary objective of this study is to evaluate the dose response, dose interval, efficacy, and safety of GSK961081 by studying three QD doses (100mcg, 400mcg and 800mcg) and three BID doses (100mc...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
7
8
9
10
Next